<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396303</url>
  </required_header>
  <id_info>
    <org_study_id>67365</org_study_id>
    <nct_id>NCT02396303</nct_id>
  </id_info>
  <brief_title>Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-partum haemorrhage is one of the life threatening emergencies. It accounts for nearly&#xD;
      one-quarter of all maternal death worldwide. Atonic uterus contributes about 80% among the&#xD;
      causes. Uterotonic drugs are administered following the delivery of baby both in vaginal and&#xD;
      caesarean delivery for prevention of PPH. However postpartum haemorrhage cannot always be&#xD;
      prevented. But, the incidence and especially its magnitude can be reduced by assessing the&#xD;
      risk factors and following the guidelines. The intelligent anticipation, skilled supervision,&#xD;
      prompt detection and effective institution of therapy can prevent a normal case from&#xD;
      undergoing disastrous consequences. This study will be carried out at Bangabandhu Sheikh&#xD;
      Mujib Medical University (BSMMU) within six months after approval. This is a Randomized&#xD;
      Control Trial which will compare efficacy of Carbetocin and Oxytocin for the control of PPH.&#xD;
      Structured Questionnaire, Data Sheet, hospital indoor documents i.e. Patient chart, operation&#xD;
      notes, surgeons visual estimation of blood loss etc will be used as study tool. Ethical&#xD;
      clearance will be obtained from Institutional Review Board of BSMMU. Written informed consent&#xD;
      will be obtained from the patient or from her legal guardian. Patient confidentiality will be&#xD;
      strictly maintained. No name, address or contact details of the patient will be divulged.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated blood loss after cesarean section</measure>
    <time_frame>24 hours of delivery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Patient receiving carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group subjects will receive intravenous Carbetocin during third stage of labour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient receiving oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator group subjects will receive intramascular Oxytocin during third stage of labour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <arm_group_label>Patient receiving carbetocin</arm_group_label>
    <arm_group_label>Patient receiving oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with risk factors for primary post-partum haemorrhage such as: multiple&#xD;
             pregnancy, one or more previous caesarean section, presence of uterine fibroids,&#xD;
             previous myomectomy, presence of placenta previa, past history of PPH, fetal&#xD;
             macrosomia and fetal malformations associated with polyhydramnios&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of hypertension, eclampsia, cardiac, renal or liver diseases, epilepsy,&#xD;
             general anaesthesia, as well as women with history of hypersensitivity to Carbetocin&#xD;
             according to the Br National Formulary. Patients unwilling to give consent for this&#xD;
             study are also excluded&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mousumi Paul, MBBS</last_name>
    <phone>+8801670789784</phone>
    <email>chayon.dmc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BSMMU</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <contact>
      <last_name>Rezaul K Kazal, MBBS, FCPS</last_name>
      <phone>+8801919000011</phone>
      <email>rkkazal@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Mousumi Paul</investigator_full_name>
    <investigator_title>FCPS Course Student</investigator_title>
  </responsible_party>
  <keyword>General: To compare Carbetocin and Oxytocin for the control of PPH.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

